RIVFLOZA

This brand name is authorized in United States.

Active ingredients

The drug RIVFLOZA contains one active pharmaceutical ingredient (API):

`1`	Nedosiran UNII `13U9R5J3WL` - NEDOSIRAN
	Nedosiran is a double-stranded siRNA, conjugated to GalNAc aminosugar residues. After subcutaneous administration, the GalNAc-conjugated sugars bind to asialoglycoprotein receptors (ASGPR) to deliver nedosiran to hepatocytes. Nedosiran reduces levels of hepatic lactate dehydrogenase (LDH) via the degradation of LDHA messenger ribonucleic acid (mRNA) in hepatocytes through RNA interference.
	Read more about Nedosiran

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RIVFLOZA Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	0169-5306, 0169-5307, 0169-5308

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.